Personal information

Activities

Collapse all

Works (14)

Fatigue patterns surrounding biologic disease-modifying antirheumatic drug injection in patients with an inflammatory rheumatic disease: an ecological momentary assessment study

Rheumatology International
2025-01-11 | Journal article
DOI: 10.1007/s00296-024-05779-y
Contributors: Jette A. van Lint; Johanna E. Vriezekolk; Naomi T. Jessurun; Alfons A. den Broeder; Bart J. F. van den Bemt; Victor J. B. Huiskes
Source: check_circle
Crossref

Prosthetic infections following tocilizumab treatment in patients with rheumatoid arthritis

Rheumatology
2024-10-01 | Journal article
DOI: 10.1093/rheumatology/keae228
Contributors: Annemieke Louters; Maikel Van Oosterhout; Lot Burgemeister; Naomi T Jessurun; Jette A Van Lint
Source: check_circle
Crossref

Quantification of longitudinal patient-reported burden of adverse drug reactions attributed to the use of TNF-α inhibitors in inflammatory rheumatic diseases: an observational prospective cohort study

Expert Opinion on Drug Safety
2024-08-30 | Journal article
DOI: 10.1080/14740338.2024.2383697
Contributors: Benthe H. König; Helen R. Gosselt; Jette A. van Lint; Leanne J. Kosse; Bart J. F. van den Bemt; Peter M. ten Klooster; Harald E. Vonkeman; Naomi T. Jessurun
Source: check_circle
Crossref

The burden of adverse drug reactions reported by patients in the Dutch ADR monitor: a proof of concept

Expert Opinion on Drug Safety
2024-07-26 | Journal article
DOI: 10.1080/14740338.2024.2383707
Contributors: Janneke M. Quik; Helen R. Gosselt; Jette A. van Lint; Leanne J. Kosse; Peter M. ten Klooster; Harald E. Vonkeman; B. J. F. van den Bemt; Naomi T. Jessurun
Source: check_circle
Crossref

Hospital registration of adverse drug reactions in electronic health records: importance and contribution to pharmacovigilance

Expert Opinion on Drug Safety
2024-07-02 | Journal article
DOI: 10.1080/14740338.2023.2282582
Contributors: Roba Alloush; Jette van Lint; Rob J. van Marum; Walter W.A.J.J. Hermens; Naomi T. Jessurun
Source: check_circle
Crossref

Development of a Framework Structuring Themes in the Course of Adverse Drug Reactions from a Patient’s Perspective

Drug Safety
2023-10 | Journal article
DOI: 10.1007/s40264-023-01343-y
Contributors: Jette A. van Lint; Marlieke Sonnenberg; Harald E. Vonkeman; Bart J. F. van den Bemt; Eugene P. van Puijenbroek; Naomi T. Jessurun
Source: check_circle
Crossref

Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor

BioDrugs
2023-07 | Journal article
DOI: 10.1007/s40259-023-00592-8
Contributors: Jette A. van Lint; Naomi T. Jessurun; Sander W. Tas; Harald E. Vonkeman; Martijn B. A. van Doorn; Frank Hoentjen; Michael T. Nurmohamed; Eugene P. van Puijenbroek; Bart J. F. van den Bemt
Source: check_circle
Crossref

First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept

Expert Opinion on Drug Safety
2023-06-03 | Journal article
DOI: 10.1080/14740338.2023.2172157
Contributors: Kimberly Velthuis; Naomi T. Jessurun; Thi D.M. Nguyen; Joep Scholl; Jurriaan R.G. Jansen; Jette A. van Lint; Leanne J. Kosse; Peter M. ten Klooster; Harald E. Vonkeman
Source: check_circle
Crossref

Sex differences in adverse drug reactions from Adalimumab and etanercept in patients with inflammatory rheumatic diseases

Expert Opinion on Drug Safety
2023-06-03 | Journal article
DOI: 10.1080/14740338.2023.2181340
Contributors: Helen R. Gosselt; Jette A. van Lint; Leanne J. Kosse; Phyllis I. Spuls; Harald E. Vonkeman; Sander W. Tas; Frank Hoentjen; Michael T. Nurmohamed; Bart J.F. van den Bemt; Martijn B.A. van Doorn et al.
Source: check_circle
Crossref

Disease-specific ADRs of TNF-α inhibitors as reported by patients with inflammatory rheumatic diseases: a registry-based prospective multicenter cohort study

Expert Opinion on Drug Safety
2023-03-04 | Journal article
DOI: 10.1080/14740338.2022.2115479
Contributors: Lieke H. Roest; Leanne J. Kosse; Jette A. van Lint; Helen R. Gosselt; Joep H.G. Scholl; Eugène van Puijenbroek; Harald E. Vonkeman; Sander W. Tas; Michael T. Nurmohamed; Bart J.F. van den Bemt et al.
Source: check_circle
Crossref

Hypoglycaemia following JAK inhibitor treatment in patients with diabetes

Annals of the Rheumatic Diseases
2022-04 | Journal article
DOI: 10.1136/annrheumdis-2021-221840
Contributors: Jette A van Lint; Florence P A M van Hunsel; Sander W Tas; Harald E Vonkeman; Frank Hoentjen; Martijn B A van Doorn; Renske C F Hebing; Michael T Nurmohamed; Bart J F van den Bemt; Eugene P van Puijenbroek et al.
Source: check_circle
Crossref

Neuropsychiatric adverse drug reactions associated with low dose methotrexate in rheumatoid arthritis patients

Expert Opinion on Drug Safety
2022-03-04 | Journal article
DOI: 10.1080/14740338.2022.2003328
Contributors: Jette A. Van Lint; Tom Bakker; Peter M. ten Klooster; Eugene P. van Puijenbroek; Harald E. Vonkeman; Naomi T. Jessurun
Source: check_circle
Crossref

Gastrointestinal Adverse Drug Reaction Profile of Etanercept: Real-world Data From Patients and Healthcare Professionals

The Journal of Rheumatology
2021-09 | Journal article
DOI: 10.3899/jrheum.201373
Contributors: Jette A. van Lint; Naomi T. Jessurun; Sander W. Tas; Bart J.F. van den Bemt; Michael T. Nurmohamed; Martijn B.A. van Doorn; Phyllis I. Spuls; Astrid M. van Tubergen; Peter M. ten Klooster; Eugene P. van Puijenbroek et al.
Source: check_circle
Crossref

Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory Diseases

Drug Safety
2020-09-25 | Journal article
DOI: 10.1007/s40264-020-00946-z
Contributors: Jette A. van Lint; Naomi T. Jessurun; Renske C. F. Hebing; Frank Hoentjen; Sander W. Tas; Harald E. Vonkeman; Martijn B. A. van Doorn; Annemieke Sobels; Phyllis I. Spuls; Eugene P. van Puijenbroek et al.
Source: check_circle
Crossref

Peer review (1 review for 1 publication/grant)

Review activity for Drug safety. (1)
How many people are using ORCID?